Re: Novartis Phase III study shows Canakinumab reduces MACE events

...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Reply New Message

Prev Message Back To Forum Threaded View Next Message

BKC

Rank: Treasurer [?]

Points: 599 [?]

Votes: 19 Score: 4.1 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Novartis Phase III study shows Canakinumab reduces MACE events

in response to

Re: Novartis Phase III study shows Canakinumab reduces MACE events

BearDownAZ

posted on Jun 22, 2017 02:12PM

Bear: You may also want to have a look at the poster at ATVB-2017 (http://www.resverlogix.com/upload/media_element/277/01/atvb-2017-poster.pdf) - zoom in on the IPA figure. IL1 appears to be down regulated in primary human hepatocytes. For some reason, this result was not highlighted in the table.